Olfr208 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the Olfr208 protein, a member of the olfactory receptor family within the G-protein-coupled receptor (GPCR) superfamily. Olfr208, like other olfactory receptors, plays a crucial role in the sensory processes that lead to the perception of smell. These receptors are located in the membranes of olfactory sensory neurons within the nasal epithelium, where they interact with specific odorant molecules from the environment. When an odorant binds to Olfr208, the receptor undergoes a conformational change that activates an intracellular signaling cascade. This cascade ultimately results in the generation of an electrical signal that is transmitted to the brain, where it is interpreted as a specific smell. Inhibitors of Olfr208 are small molecules designed to bind to the receptor's odorant-binding site or other functionally important regions, thereby blocking the receptor's ability to interact with odorant molecules and preventing the initiation of the olfactory signal transduction process.
The development of Olfr208 inhibitors involves a detailed understanding of the receptor's structural and functional characteristics, particularly its binding pocket and the molecular interactions that facilitate odorant recognition and signal transduction. Researchers often employ high-throughput screening techniques to identify initial lead compounds that show potential for inhibiting Olfr208 activity. These lead compounds are then optimized through structure-activity relationship (SAR) studies, where modifications to their chemical structures are made to enhance their binding affinity, specificity, and stability within the receptor's binding site. The chemical structures of Olfr208 inhibitors are diverse, often incorporating functional groups that enable strong and specific interactions with the receptor. These interactions may include hydrogen bonding, hydrophobic contacts, and van der Waals forces, which are critical for stabilizing the inhibitor within the receptor's binding pocket. Advanced structural biology techniques, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are used to visualize these interactions at an atomic level, providing valuable insights that guide the design and refinement of these inhibitors. Achieving high selectivity is a key objective in the development of Olfr208 inhibitors, ensuring that these compounds specifically target Olfr208 without affecting other olfactory receptors or GPCRs with similar structural features. This selectivity is crucial for enabling precise modulation of Olfr208 activity, allowing researchers to investigate its specific role in olfactory perception and to deepen their understanding of the molecular mechanisms underlying the sense of smell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A multi-kinase inhibitor, possibly affects pathways involving Olfr208 by inhibiting cell proliferation signals. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR inhibitor, may alter cell signaling processes relevant to Olfr208's function. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR and HER2 inhibitor, potentially modifies signaling cascades related to Olfr208 activity. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
A multi-targeted kinase inhibitor, could influence pathways intersecting with Olfr208's signaling. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
EGFR inhibitor, might modulate signaling networks in which Olfr208 is involved. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Inhibits multiple receptor tyrosine kinases, potentially impacting pathways relevant to Olfr208. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
A multi-targeted receptor tyrosine kinase inhibitor, could affect Olfr208-related signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src-family kinase inhibitor, may have an indirect influence on Olfr208 by altering related signaling mechanisms. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
An irreversible EGFR family inhibitor, potentially affects pathways linked to Olfr208. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
ALK inhibitor, could modify signaling cascades that intersect with Olfr208's role. | ||||||